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TarTreatment
Sofia Pavanello and Angelo Gino Levis
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Peripheral blood lymphocytes (PBL) from psoriatic patients therapeutically exposed to polycyclic aromatic hydrocarbons (PAH) during coal tar (CT)
treatment were used to evaluate the in vivo formation of benzo[alpyrene diol epoxide(BaPDE)-DNA adducts by an ELISA technique and by the
32P-postlabeling method. Moreover, we controlled if the pretreatment with CT influences the formation of BaP-DNA adducts and the BaP metabo-
lism in the PBL obtained from psoriatic patients, treated in vitro with BaP. Our data did not show any significant influence of the CT treatment on the
levels of PAH-DNA adducts. Moreover, the use of PBL from psoriatic patients, treated in vitro with BaP, did not allow to detect significant
modifications of the metabolic activation of BaP and of the ability of its metabolites to bind to DNA, before and after CT treatment. Thus, PBL do not
seem to represent an useful cell model to evaluate the possible genotoxic effect of the exposure through the skin of psoriatic patients to the PAH
contained in CT. -Environ Health Perspect 102(Suppl 9):95-99 (1994)
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Introduction
Polycyclic aromatic hydrocarbons (PAH) are
widely distributed in the environment and
the exposure ofhumans to PAH is thought
to be responsible, at least partly, for the
higher lung cancer incidence in smokers than
in nonsmokers, and in some groups ofwork-
ers than in the general population (1,2).
Epidemiological studies have also indicated
an association between human occupational
exposure to coal tar (CT), which is generally
characterized by an high content of PAH,
and skin cancer (3). Pharmaceutical grade
CT solutions are also employed for therapeu-
tical purposes, e.g., for the treatment ofpso-
riasis, which is a common proliferative skin
disease, not accompanied by malignant cell
transformation, that affects 2 to 3% of the
human population (4). The high exposure of
psoriatic patients to genotoxic agents is docu-
mented by the exceptional levels of PAH
metabolites and/or mutagenic compounds
excreted in their urine, as well as by the sig-
nificant levels of chromosomal damages
detected in their lymphocytes (5).
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PAH require metabolic activation to
exert their carcinogenic activity. In particu-
lar, the metabolism ofbenzo[a]pyrene (BaP),
which is the most widely studied carcino-
genic PAH compounds, is highly stereoselec-
tive: over 30 different metabolites have been
identified, among which the carcinogenic
activity was related to the formation of BaP
diol epoxide (BaPDE) intermediates (6).
Since the covalent binding of the reac-
tive carcinogenic metabolites with DNA is
believed to be the first step in the initiation
of the carcinogenic process (7), the moni-
toring of PAH-DNA adducts has been
included in studies ofhuman exposures to
carcinogens as a very sensitive molecular
index providing the quantitative measure-
ments of the biologically effective dose of
the environmental carcinogens (8).
In experimental animals, DNA adduct
levels in target tissues are related to the dose
administered to the animal and the ultimate
carcinogenic response (9). In human studies,
target tissue samples can hardly be obtained.
The relative ease with which peripheral
human blood lymphocytes (PBL) can be col-
lected prompted the use ofPBL as a surro-
gate for the target tissues in order to detect
the effects ofhuman exposure to environ-
mental genotoxic agents and to study the in
vitrometabolism ofsuch agents.
Materials and Methods
SubjectsAnalyzed
Male psoriatic patients, presenting cuta-
neous lesions involving 20 to 100% ofthe
body surface, excluding the genital area and
hands, were analyzed. The patients were
hospitalized in the Dermatology Clinic of
the University of Padora (Italy). For each
patient data regarding the age, smoking
habits, occupational or consistent environ-
mental exposure to PAH, medical history,
domiciliary treatments for psoriasis and
drugs taken during the coal tar therapy,
were collected, the most relevant ofwhich
are reported in Table 1. During hospital-
ization, some of the patients were treated
with crude coal tar (CT) either alone or in
association with a CT-based paste (TP)
containing 50% coal tar, sometimes in
association with UV-irradiation, or with a
2% coal tar ointment (TO). Controls were
male healthy subjects, 25 to 50 years old,
free from chronic illness, none subjected to
medical prescription or exposures to ioniz-
ing radiation or industrial chemicals at
work. Nonsmokers were selected as indi-
viduals who had never smoked and smok-
ers those consuming 15 or more cigarettes
per day at least three months prior to
donating the blood.
Celland DNAIsolation
Samples of peripheral blood (20-30 ml)
were collected by venapuncture in hepa-
rinized plastic syringes. The purity of the
DNA, isolated from cell lysates by cycles of
phenol/chloroform extraction (10,11), was
checked and quantified by UV spec-
troscopy (the absorbance ratios of DNA at
260/230 nm and 260/280 nm were usually
>2.3 and >1.8, respectively).
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Table 1. Age, smoking habits, treatment protocol followed, and method of detection of BAPDE-DNA
adducts in control human subjects and in psoriatic patients following therapywith coal tar.
Smokinga
Subject Age habits
1 51 S
2 25 S
3 37 S
4 56 NS
5 58 NS
6 47 NS
7 NA NA
8 NA NA
9 23 S
10 NA NA
11 24 NS
12 58 NS
13 60 NS
14 16 NS
15 48 S
16 60 S
17 34 S
18 45 S
19 58 NS
20 31 NS
21 52 S
22 42 S
23 40 S
1 65 NS
2 38 S
3 47 NS
4 56 NS
5 35 NS
6 43 NS
7 52 S
8 34 S
9 61 NS
10 25 NS
11 25 NS
12 27 S
13 30 S
14 30 NS
15 30 NS
16 25 NS
17 50 NS
1 49 S
2 50 NS
3 43 S
4 65 NS
5 60 NS
6 56 NS
7 30 NS
8 79 NS
9 27 NS
10 70 S
11 25 S
12 26 NS
13 30 NS
14 32 S
15 26 NS
Days of
treatment
8
7
6
6
13
8
6
13
7
7
10
8
6
3
17
9
5
11
6
5
10
10
10
8
8
8
8
8
8
8
8
8
4
6
4
4
4
10
4
8
6
6
Type ofb
treatment
TP
TP
CT, TP
TP
TP
TP
CT, TP
CT, TP
TP
CT
TP
TP
TP
TP
CT, TP
TP
TP
CT, TP
TP
TP
TO
TO
TO
TP
TP
TP
TP
TP
TP
TP
TP
TP
TP
TP
TP
TP
TP
TP
TP
TP
TP
TP
% Body surface
with lesions
75
80
80
65
35
80
40
20
35
60
20
30
70
75
20
70
70
30
60
60
80
80
80
70
70
70
100
60
90
100
100
80
30
90
80
80
80
80
80
80
40
80
Method of detection of
BaPDE-DNA adducts
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as. smoker; NS, non-smoker; NA, data not available. bCT, pure coal tar; TP, coal tar based paste; TO, coal tar
based ointment; UV, ultraviolet radiation.
DetectionofBaPDE-DNAAdducts
(ELISAand32P-posdabefing)
ELISA assays were performed as described
elsewhere (10) using rabbit anti BaPDE-
DNA polyclonal antiserum (F29). Human
DNAsamples were tested in two to six sep-
arate experiments (depending on the
amount of DNA available). In addition
each sample was assayed in triplicate or
quadruplicate within each experiment.
Different concentrations of3H-BaPDE-
DNA standard were assayed in each experi-
ment in quadruplicate. All assays were
performed blindly by coding test samples.
DNA adducts were also detected by
32P-postlabeling as described elsewhere
(11). Five pg DNA for each sample were
digested for 3 hr and 30 minutes at 37°C
with 250 mU micrococcal nuclease and
8m U spleen phosphodiesterase. Samples
were further digested for 30 minutes with 2
pg nuclease P1. After the addition of 0.5
mM Tris-base buffer, the digested DNA
was labeled with 20 pCi of32P-ATP, 2.5
units ofT4 polynucleotide kinase. After 30
minutes, the reaction was terminated by
adding 40 mM potato apyrase. Purification
and resolution of32P-labeled adducts were
carried out on polyethyleneimine-cellulose
TLC sheets.
The isolation ofthe DNA adducts was
also obtained by twice subsequent butanol
extractions of the digested DNA samples,
essentially as described by Gupta (12).
The chromatograms were visualized by
autoradiography at -80°C, using intensify-
ing screens. Adduct levels were determined
by excising the marked areas of the chro-
matograms, the radioactivity ofwhich was
measured by Cerencov counting. Relative
adduct labeling (RAL) was calculated on
the basis ofthe amount ofradioactivity on
the chromatograms, the DNA amount,
and the specific activity ofthe [32-P] ATP
used for the labeling (11). In each experi-
ment a 3H-BaPDE-DNA standard with a
known modification level was included
(recoveries of80-100% were obtained).
The formation of BaPDE-DNA ad-
ducts in PBL treated in vitro for 24hr with
the BaP active metabolite, 2p M (-)-BaP-
7,8-dihydrodiol, was determined by quan-
tifying by the HPLC technique the
amounts of their hydrolisis products, the
BaP-tetrols. To this purpose the (-)-BaP-
7,8-dihydrodiol metabolites were extracted
twice by adding to the culture medium an
equal volume of ethyl acetate, saturated
with Tris-HCl 10 mM pH 7.5 buffer, and
separated by HPLC using a Resolve C18
column as previouslydescribed (13,14).
Results and Discussion
Detecdon ofBaPDE-DNAAdducts in
PBLfromPsoriaticPatients byELISA
The levels of BaPDE-DNA adducts
were determined by an ELISA assay in the
PBL of 23 psoriatic patients during CT
treatment and 2 to 5 months later (Figure
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Figure 1. DNA adducts in PBL of psoriatic patients
detected by ELISA technique (A), and the 32P-postla-
beling method using the nuclease P1 (B) or the butanol
extraction procedure (C). Figure 1A: I, during CT treat-
ment; II, 2-5 months after the end of treatment.
Figures 1B and 1C: I, before clinical therapy with CT; II,
after 8 days of continuous CT application and, III, 16
days after the end of CTtherapy.
IA). We found that the mean adduct level
during CT treatment was 7.7 ± 4.9
adducts/108 nucleotides, a level compara-
ble to those reported for subjects occupa-
tionally exposed to PAH. In nine ofthe 10
patients examined 2 to 5 months after the
end ofCT therapy, the mean adduct level
was significantly lowered down to 3.3 ± 2.4
adducts/108 nucleotides, suggesting a rela-
tively short persistence ofthe DNAdamage
induced by PAH in human PBL.
Detection ofPAH-DNAAdducts in
PBLofPsoriaticPatients bythe32p-
PosdabelingMethod
The 32P-postlabeling method is perhaps at
present the most widely used technique for
monitoring the human exposure to PAH.
We quantified PAH-DNA adducts by the
32P-postlabeling technique using both
nuclease P1 enrichment and the butanol
extraction procedures. Figure 1B shows the
levels of total- and anti-BaPDE-DNA
adducts in the 26 PBL samples obtained
from the nine psoriatic patients and in the
PBL samples from the 8 healthy subjects,
using the nuclease P1 enrichment proce-
dure. No statistically significant difference
was found among the mean total DNA-
adduct level before clinical therapywith TP
(0.46 ± 0.18 adducts/108 nucleotides),
after 8 days of continuos TP application
(0.54 ± 0.36 adducts/108 nucleotides), and
16 days after the end of TP treatment
(0.53 ± 0.26 adducts/108 nucleotides).
Moreover, in healthy subjects the mean
level of adducts (0.32 ± 0.24 adducts/108
nucleotides) was not statistically different
from the mean levels ofadducts in psoriatic
patients. The autoradiograms of DNA
adducts in the analyzed PBL samples
revealed the presence of radioactive spots
mainly in a distinct diagonal radioactive
zone (DRZ) which is typical for aromatic
DNA adducts (15,16). The same DRZ
was found in 32P-postlabeling digests of
DNA from human skin mantained in
short-term organ culture after treatment
with CT-ointments (17), in DNA from
PBL and from lung cells of lung cancer
patients (16), and was shown to consist of
a multitude of DNA adducts containing
aromatic hydrophobic moieties, as indi-
cated by their chromatographic behaviour
(15). It must be noticed that only in seven
samples ofDNA from psoriatic patients we
were able to detect the specific spot corre-
sponding to the anti-BaPDE-DNA adduct.
Figure IC shows the levels of total-
DNA adducts in the 18 PBL samples
obtained from the nine psoriatic patients
using the butanol extraction procedure.
Also, in this case no statistically significant
difference was found among the mean total
DNA adduct level before clinical therapy
with TP (0.74 ± 0.38 adducts/10
nucleotides), after 8 days ofcontinuous TP
application (0.68 ± 0.25 adducts/108
nucleotides) and 16 days after the end of
TP treatment (0.79 ± 0.25 adducts/108
nucleotides).
Moreover, although the comparison
between the mean total DNA-adduct levels
detected by the nuclease P1 method (0.58
± 0.31 adducts/108 nucleotides) and that
detected by the butanol method (0.73 ±
0.30 adducts/108 nucleotides) did not
reveal anysignificant difference, the autora-
diograms of 18 DNA samples obtained by
the butanol procedure revealed the pres-
ence of a-dditional radioactive spots not
detected by the nuclease P1 method.
Comparison between theLevel of
Aromatic-DNAAdducts Detectedby
theELISAMethodandthe32P-posda-
belingTehnique inthe PBLfrom
Psoriatic Patients
It must be noticed that the mean BaPDE-
DNA-adduct level we detected by the
ELISA method in the PBL of psoriatic
patients is about 20 to 100 times higher
than that we found by the 32P-postlabeling
technique on the same cell system. Other
authors (18,19), using ELISA methods,
found in the DNA from lung tissues of
lung cancer patients BaPDE-DNA levels 5
to 10 times higher than those determined
by the 32P-postlabeling technique. In other
studies, the postlabeling values of DNA
adducts were significantly (10-100 fold)
lower than those obtained by ELISA (20).
The discrepancy between the results
obtained by the two methods can be
explained by cross reactivity of the anti-
serum against different DNA adducts,
which enhances the responsiveness of the
ELISA method as opposed to structurally
related PAH adducts (19). The underesti-
mation observed with postlabeling may
also be due to some intrinsic proprieties
such as poor efficiency ofphosphorylation
(20). Moreover, the nuclease P1 digestion
of DNA, which is used in the present as
well as in other studies to enhance the sen-
sitivity of the 32P-postlabeling assay, may
result in dephosphorylation of certain
adducts, impeding their 32P-postlabeling,
and may give an underestimation of the
actual adduct level (20).
Benzo[a]pyreneMetabolism andDNA
AdductFormation in CulturedPBLof
PsoriaticPatients
The topical application of CT solution to
neonatal rats was shown to induce the aryl
hydrocarbons hydroxylases AHH of skin
and liver (21). The AHH in the skin of
psoriatic patients have a lower activity and
inducibility than in control subjects (22).
Therefore, we evaluated the possibility that
the treatment with CT influences the BaP
activation and the binding of its metabo-
lites to DNA. PBL samples, from five
healthy subjects and 10 psoriatic patients,
were analyzed after treatment in vitro with
2 pM (-)-7,8-dihydrodiol for 24 hr. The
metabolism of (-)-7,8-dihydrodiol to syn-
and antistereoisomers ofBaPDE was deter-
mined by monitoring the formation of
their corresponding tetrols: BaP-7,10/8,9
and BaP-7/8,9,10 for (+)-anti-BaPDE, and
BaP-7,9/8,10 and BaP-7,9,10/8 for (-)-syn-
BaPDE. As shown in Figure 2, anti-tetrols
were the predominant isomers in all the
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Figure 2. Ratio of anti/syn BaP-tetrols, formed in vitro
by PBL of psoriatic patients and healthy subjects after
treatment with (-)-BaP-7,8-dihydrodiol, and detected by
HPLC. PBL were obtained from psoriatic patients
before (1) or 4 to 10 days after the end of CT therapy
(11), and from healthy subjects reanalyzed 2 to 3 times
at distance of 10 days from one another(l, 11).
examined PBL samples (mean ratio anti-
/syn-tetrols: 23.2 ± 10.83), but significant
levels ofsyn-tetrols, which clearly derived
from the hydrolysis of (-)-syn-BaPDE,
were also present. The mean ratio ofanti-
/syn-tetrols in healthy subjects (5.7 ± 0.35)
was significantly lower than in psoriatic
patients (32.1 ± 15.25) (p<0.001), whereas
statistical comparison ofthis ratio in psori-
atic patients, before and after treatment
with CT, did not reveal any significant dif-
ference.
The analysis by HPLC of the DNA
adducts, after incubation of lymphocytes
with unlabeled 2 pM (-)-BaP-7,8-dihydro-
diol for 24 hr (13), showed the formation
of consistent amounts of (-)-syn-BaPDE-
DNA adducts in the 15 PBL samples both
from healthy subjects and psoriatic
patients. The mean ratio ofanti-BaPDE-
DNA/syn-BaPDE-DNA adducts was 4.01
± 3.27 pmol/'pgDNA, and no significant
difference in that ratio was found either
between healthy subjects and psoriatic
patients, or between psoriatic patients,
before and after CT treatment (13).
Conclusion
The purpose ofour study was to evaluate
the genotoxic risk involved in the exposure
ofpsoriatic patients to PAH by the detec-
tion of PAH-DNA adducts in their DNA
isolated from PBL. Our data demonstrate
no correlation between the levels of PAH-
DNA adducts and the exposure to CT.
With the lack of correlation between CT
therapy and incidence of skin cancer in
psoriatic patients (4), such data suggest
that CT treatment ofpsoriasis should not
be considered a potential genetic and car-
cinogenic risk for psoriatic patients.
However, it must be notice that the DNA-
adduct levels in nontarget tissues, like PBL,
could not reflect the level of adducts in
skin and lung cells, both ofwhich have
been shown to be the target tissues for
DNA in human PAH exposures
(14,23,24). Therefore, the lack ofelevated
DNA adducts in PBL, although represent-
ing a relevant information related to bio-
monitoring, does not allow to directly
predict the skin cancer risk involved in CT
therapies.
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